Company Overview
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +468.67% |
| 6 Months: | +30.80% |
| 3 Months: | +68.36% |
| 1 Month: | +36.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.21 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMMX Immix Biopharma, Inc. R3KPHARMA | 13.25 | -15.06 | $947.90M | 0.00% | -31.62% | -34.18% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.68M | 6.72M | 7.66M | 10.89M | 10.80M | - |
| Operating Income | -162.52K | -243.16K | -347.99K | -1.33M | -1.56M | -1.53M | -2.52M | -3.72M | -4.52M | -5.59M | -4.70M | -7.39M | - | -4.68M | -6.72M | -7.66M | -10.89M | -10.80M | -12.46M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.62M | -6.64M | -7.53M | -10.80M | -10.67M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.53M | -6.61M | -7.58M | -10.68M | -10.09M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.82K | 8.91K | 7.72K | 11.27K | 0 | - |
| Net Income | -1.02M | -208.64K | -403.26K | -1.33M | -1.56M | -1.54M | -2.48M | -3.58M | -4.28M | -5.26M | -4.39M | -7.15M | - | -4.54M | -6.62M | -7.59M | -10.69M | -10.09M | -11.56M |
| Diluted EPS | - | - | - | - | -0.11 | -0.11 | -0.18 | -0.24 | -0.23 | -0.22 | -0.15 | -0.24 | - | -0.15 | -0.22 | -0.24 | - | -0.18 | -0.18 |
| R&D Expense | 24.84K | 62.76K | 29.69K | 629.53K | 607.75K | 695.94K | 1.32M | 2.21M | 2.11M | 3.25M | 2.22M | 4.45M | - | 1.98M | 3.97M | 4.58M | - | 5.98M | 5.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -453.85K | -1.35M | -8.22M | -16.14M | -22.67M | -29.96M |
| Net Income | -1.15M | -24.38M | -8.23M | -15.43M | -21.61M | -29.44M |
| Diluted EPS | - | - | -0.59 | -0.89 | -0.76 | -0.89 |
| R&D Expense | 248.15K | 126.53K | 4.20M | 8.74M | 11.29M | 16.26M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 539.60K | - | 14.91M | 19.93M | 22.95M | 104.84M |
| Current Assets | - | - | - | 14.90M | 19.79M | 20.20M | 101.24M |
| Cash & Equivalents | - | 391.09K | - | 13.44M | 17.51M | 17.68M | 93.93M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 255.71K | 1.17M | 1.97M | 0 |
| Total Liabilities | - | 5.27M | - | 1.75M | 3.72M | 9.70M | 11.04M |
| Current Liabilities | - | 5.27M | - | 1.27M | 3.72M | 8.69M | 10.11M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | 50.00K | - | 0 | 1.07M | 1.07M |
| Total Equity | -3.65M | -4.73M | - | 13.16M | 16.41M | 13.25M | 93.80M |
| Shares Outstanding | - | - | - | 13.96M | 19.99M | 27.61M | 53.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -404.69K | -1.59M | -7.41M | -11.37M | -14.60M | -23.93M |
| Investing Cash Flow | - | -802 | - | -52.09K | -1.18M | -7.21M |
| Financing Cash Flow | - | 18.85M | 3.23M | 15.46M | 15.95M | 107.39M |
| Capital Expenditure | - | -802 | - | -52.09K | -1.18M | -732.92K |
| Free Cash Flow | - | -1.59M | - | -11.42M | -15.77M | -24.66M |
| Share Buybacks | - | - | 99.96K | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 24.3% | - | -62.5% | -94.0% | -163.1% | -31.4% |
| ROCE % | 9.6% | - | -60.3% | -99.6% | -159.0% | -31.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 13.68% | 9.78M | $122.29M |
| 2 | Saturn V Capital Management LP | 6.51% | 4.66M | $58.23M |
| 3 | Eventide Asset Management LLC | 5.44% | 3.89M | $48.64M |
| 4 | State Street Corporation | 4.19% | 3.00M | $37.46M |
| 5 | Blackrock Inc. | 4.18% | 2.99M | $37.37M |
| 6 | Deep Track Capital, Lp | 3.88% | 2.77M | $34.69M |
| 7 | Vanguard Capital Management LLC | 3.50% | 2.51M | $31.34M |
| 8 | Opaleye Management Inc. | 3.28% | 2.35M | $29.31M |
| 9 | Millennium Management Llc | 2.89% | 2.07M | $25.83M |
| 10 | UBS Group AG | 2.71% | 1.94M | $24.27M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMMX
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQTl9oNzJfbGpHVkl3bGdNUTVLM1lqamI3Sy1QcmM1YzN6bWJkN1p1dFZjS2JCcUhlZnA3Z3V5VHlxaFlqdU5vTUE4ekktZVp1YkVrQi13Rjg5M3VyaDdmRWVTRDBkVTRndHNQY0FHdE92dXJHeHp1bnpYbUl1bGVhdExsMGdpeElMSGQ5ck…
(IMMX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPdW9QVkVndGdYSlEyb0oyMFVmLS1hOHcxdWFXQWtDbEc2R2ZxV09lWG9od1pNcHpaUUpLSXBWVkgweGprVGJCRmJENkM0VHhIbFZfVXlaV1JrMUI2MmZid3VoZW5YLTdJSjFpRlY0dXBnQlhZV211dGszRWloekVCTUtRemVlcUh2UWpqQ0…
IMMX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFB1dlh6SVpUcjBTai1UM2NpOU0tc2g2Zzd3WTJHbGJ4YlRJYmZsQ0Y5YUxqOTVPLXpLb2E2OVZCZjRleHRlcENmc1hwaTNLbmdreGNCNG5WOHp0d25jMkIzdnV2a2xhNXo2NkE1M01JdzhCZ3Jlb0s0Vnhn?oc=5" target="_blank">IMM…
IMMX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE40TUNTNDQ5TkF2WnkwSk5RN0VqWTB6ODFKTDFNVUtLVF9DMmtBTmhNdkJsVVpza0E0anVMMXhwVGU3cnVFdWc?oc=5" target="_blank">IMMX</a> <font color="#6f6f6f">Finviz</font>…
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQbUhCNnYxcklxYkVzVUlPRElmUHNrdVpGdkc4NFdVWHdxSlRQMjMzYk13Q3EzMWhIY3VPdEFFUzJFSVFLS0lSa3NVTXc1eGI1YTBPNmhrZXh0M29Ja3IxblhuTGlsLUg3dm5SSkxueC0zeXk0M2FCMWJZaElFRjljbktaQmZYWUdzZ0JtUm…
Immix Biopharma stock tumbles amid fugitive CMO report - Investing.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNZnRVTHU4V2hwSnI0T0hPRDRQWFRIaXRIbm9FaVBwN1NMRjYxTEQxSHJ6R0cwcXJZb0s1SU5QaHZ5NUFtRlhIdl9GeDNpZjdGVmdkVTV3VVpKa3FTdWdjT0JuV1AzNUFpQkxDTmdPYklQQzJPbURFdVo5WjgtOWl0Ym91Q1pIYUE3a0p6Q0…
IMMX — Frequently Asked Questions
What is the current share price of Immix Biopharma, Inc. (IMMX)?
As of 2026-09-19 21:16 PDT, Immix Biopharma, Inc. (IMMX) trades at $13.25 on NasdaqCM. Its 52-week range is $1.96 to $14.47.
What is the market capitalisation of IMMX?
Immix Biopharma, Inc. (IMMX) has a market capitalisation of $947.90M on NasdaqCM.
What is the P/E ratio of IMMX?
IMMX trades at a trailing price-to-earnings (P/E) ratio of -15.06. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.91.
What is the return on equity (ROE) of IMMX?
IMMX has a return on equity (ROE) of -34.18%. Its return on capital employed (ROCE) is -31.62%.
Is IMMX a good stock to buy?
This page provides a data-driven analysis of Immix Biopharma, Inc. (IMMX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.